Differences in Cerebral Small Vessel Disease in Patients with Dementia in Alzheimer’s Disease Compared to Patients with Dementia in Distal Cerebral Atherosclerosis
Main Article Content
Abstract
Background: The number of people with dementia is constantly increasing and currently amounts to over 55 million people worldwide. Common causes leading to its progression are Alzheimer's disease and distal cerebral atherosclerosis. These diseases are accompanied by the development of specific Cerebral Small Vessel Disease.
Aims: This research is devoted to comparing Cerebral Small Vessel Disease caused by Alzheimer's dementia to Cerebral Small Vessel Disease, developing in dementia caused by distal cerebral atherosclerosis.
Methods: For the research, 1024 dementia patients aged 28-81 (mean age 77.5) were selected, 719 males (70.22%), 305 females (29.78%).
Test Group 1. 93 (9.08%) patients had Alzheimer's disease. According to dementia severity, the patients were divided into: a preclinical stage (dementia TDR-0) - 10, a mild stage (dementia TDR-1) - 26, a moderately severe stage (dementia TDR-2) - 40, a severe stage (dementia TDR-3) - 17 people.
Test Group 2. 931 (90.92%) patients had distal cerebral atherosclerotic lesions. Of these: 52 (5.59%) had early signs of chronic cerebrovascular insufficiency, 484 (51.99%) had pronounced signs of chronic cerebrovascular insufficiency, 306 (32.87%) had severe chronic cerebrovascular insufficiency, 27 (2.90%) had Binswanger's disease, 62 (6.66%) had vascular parkinsonism. According to dementia severity, patients were divided into: 445 (47.80%) with unpronounced dementia, 332 (35.66%) with CDR-1 dementia, 132 (14.18%) with CDR-2 dementia, and 22 (2.36%) with CDR-3 dementia.
Results:
Test Group 1. In all 93 cases, dyscirculatory angiopathy of Alzheimer’s type was detected, which is manifested in atherosclerosis absence, reduction of capillaries in the temporal regions, large arteriovenous shunts development, venous trunks expansion, discharge of arterial blood into the venous bed, and venous stasis.
Test Group 2. In all 931 cases, multiple distal cerebral atherosclerotic lesions were detected, combining stenosis and occlusion, small arteriovenous shunts, absence of pathological venous trunks, venous stasis.
Conclusion: In Alzheimer's disease, Cerebral Small Vessel Disease has a specific type of changes characteristic only to this disease, which are manifested in Dyscirculatory angiopathy of Alzheimer's type.
In distal cerebral atherosclerosis, Cerebral Small Vessel Disease manifests itself in atherosclerotic lesions of the distal arteries, arterioles and capillaries. These lesions are not found in Alzheimer's disease.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. World Health Organization. Dementia: Key facts. https://www.who.int/news-room/fact-sheets/detail/dementia
3. Gjulev NM, Pustozertsev VG, Gjulev SN. Cerebrovascular Diseases. Moscow BINOM, 2002.
4. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010; 9, 7: 689–701. DOI: 10.1016/S1474-4422(10)70104-6
5. Cai Z, Wang C, He W, et al. Cerebral small vessel disease and Alzheimer's disease. Clin Interv Aging. 2015; 23, 10: 1695-1704. https://doi.org/10.2147/CIA.S90871
6. Sabayan B, Goudarzi R, Ji Y, Borhani‐Haghighi A et al. Intracranial Atherosclerosis Disease Associated With Cognitive Impairment and Dementia: Systematic Review and Meta‐Analysis. JAHA, 2023; 12, 22: 1-11.
https://doi.org/10.1161/JAHA.123.032506
7. Grammas P, Martinez J, Sanchez A, et al. A new paradigm for the treatment of Alzheimer's disease: targeting vascular activation. J Alzheimers Dis 2014; 40, 3: 619-630. https://doi.org/10.3233/JAD-2014-132057
8. Alzheimer’s Association. 2019 Alzheimer’s Disease Facts and Figures. Special report: Alzheimer's detection in the primary care setting — connecting patients with physicians. Alzheimer's & Dementia 2019; 15, 3: 321-387.
https://doi.org/10.1016/j.jalz.2019.01.010
9. Mormino EC, Papp KV, Rentz DM, et al. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid-β. J Alzheimer's & Dementia February 27, 2017; 1-9, http://dx.doi.org/10.1016/j.jalz.2017.01.018
10. Maksimovich IV and Polyaev Yu A The importance of early diagnosis of dyscircular angiopathy of Alzheimer’s type in the study of heredity of Alzheimer’s disease. Journal of Alzheimer’s & Dementia, 2010; 6, e43.
https://doi.org/10.1016/j.jalz.2010.08.133
11. Maksimovich IV. Dyscirculatory Angiopathy of Alzheimer’s Type. Journal of Behavioral and Brain Science. 2011; 1, 2: 57-68. doi: 10.4236/jbbs.2011.12008
12. Maksimovich IV. Certain new aspects of etiology and pathogenesis of Alzheimer’s disease. Advances in Alzheimer’s Disease, 2012; 1, 3:68-76. doi: 10.4236/aad.2012.13009
13. Maksimovich IV. Cerebrovascular Changes and Cerebral Atrophy in the Development of Dementia during Alzheimer's Disease. Medical Research Archives. 2023; 11 (5): 1-10. https://doi.org/10.18103/mra.v11i5.3869
14. Zlokovic BV. Neurodegeneration and the neurovascular unit. Nat Med 2010; 16, 12 1370-1371. doi: 10.1038/nm1210-1370.
15. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 2010; 120, 3 287-396. doi: 10.1007/s00401-010-0718-6.
16. Zlokovic BV Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nature Reviews Neuroscience. 2011; 3 723-738. https://doi.org/10.1038/nrn3114
17. Kalaria R Small vessel disease and Alzheimer’s dementia: Pathological considerations. Cerebrovascular Diseases. 2002; 13: 48-52. doi: 10.1159/000049150.
18. Baloiannis SJ and Baloiannis IS. The vascular factor in Alzheimer’s disease: A study in Golgi technique and electron microscopy. Journal of the Neurological Sciences 2012; 322: 117-121. doi: 10.1016/j.jns.2012.07.010
19. Kimbrough IF, Robel S, Roberson E D, Sontheimer H. Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease. Brain 2015; 138, Pt 12 3716-3733. https://academic.oup.com/brain/article/138/12/3716/416119
20. Baloyannis SJ. Brain capillaries in Alzheimer's disease. Hell J Nucl Med 2015; 18, Suppl 1 152.
21. De la Torre JC Cerebral Perfusion Enhancing Interventions: A New Strategy for the Prevention of Alzheimer Dementia. Brain Pathology 2016; 26, 5: 618–631. https://doi.org/10.1111/bpa.12405
22. Morel F. An apparently dyshoric and topical angiopathy. Monatsschr Psychiat Neurol 1950; 120, 5-6 352-357.
23. Maksimovich IV. Study of the Impact of Transcatheter Intracerebral Laser Photobiomodulation Therapy Treatment on Patients with Alzheimer's Disease and Binswanger's Disease. Medical Research Archives. 2022; 10, 12: 1-13. https://doi.org/10.18103/mra.v10i12.3420
24. Bell RD and Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathologica. 2009; 118: 103-113. https://link.springer.com/article/10.1007/s00401-009-0522-3
25. Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP. et all. Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015; 85, 2: 296-302. doi: 10.1016/j.neuron.2014.12.032.
26. Maksimovich IV. Transcatheter intracerebral photobiomodulation in degenerative brain disorders: clinical studies (Part 1). In Photobiomodulation in the Brain, Edited by Michael R. Hamblin, Ying-Ying Huang. Academic Press is an imprint of Elsevier, London, 2019; p-p. 515-528. https://doi.org/10.1016/B978-0-12-815305-5.00038-5
27. Brown WR, Thore CR Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol. 2011; 37, 1: 56-74. https://doi.org/10.1111/j.1365-2990.2010.01139.x
28. Maksimovich IV. Transcatheter intracerebral photobiomodulation in ischemic brain disorders: clinical studies (Part 2). Photobiomodulation in the Brain. Edited by Michael R. Hamblin, Ying-Ying Huang, Academic Press is an imprint of Elsevier, London, 2019; 529-544. https://doi.org/10.1016/B978-0-12-815305-5.00039-7.
29. Pasi M. Cordonnier Ch. Clinical Relevance of Cerebral Small Vessel Diseases. Stroke. 2020; 51, 1: 47-53.
https://doi.org/10.1161/STROKEAHA.119.024148
30. Tomimoto H. Subcortical vascular dementia. Neurosci Res. 2011; 71, 3 193-199.
https://doi.org/10.1016/j.neures.2011.07.1820
31. Maksimovich IV. Intracerebral Transcatheter Laser PBMT in the Treatment of Binswanger's Disease and Vascular Parkinsonism: Research and Clinical Experience. Photobiomodul Photomed and Laser Surg. 2019; 37, 10: 606-614. https://doi.org/10.1089/photob.2019.4649
32. Akiguchi I, Budka H, Shirakashi Y, Woehrer A, et all. MRI features of Binswanger's disease predict prognosis and associated pathology. Ann Clin Transl Neurol. 2014; 1, 10: 813-821. https://doi.org/10.1002/acn3.123
33. Grodstein F, Leurgans SE, Capuano AW, Schneider JA, Bennett DA. Trends in Postmortem Neurodegenerative and Cerebrovascular Neuropathologies Over 25 Years. JAMA Neurol. 2023; 80, 4: 370-376.
doi: 10.1001/jamaneurol.2022.5416
34. Morris JC. The Clinical Dementia Rating (CDR): Current Version and Scoring Rules. Neurology. 1993; 11 (43): 2412-2414. https://doi.org/10.1212/WNL.43.11.2412
35. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12, 3: 189-198. https://doi.org/10.1016/0022-3956(75)90026-6
36. Maksimovich IV, and Gotman LN. Method of complex radiation diagnostics at preclinical and clinical stages of Alzheimer’s disease. Russian Patent, No. 2315559. 2006.
37. Maksimovich IV. The tomography dementia rating scale (TDR) - The rating scale of Alzheimer’s disease stages. Health. 2012; 4, 9 A: 712-719. doi: 10.4236/health.2012.429111
38. Nelson AR, Sweeney MD, Sagare AP, Zlokovic BV. Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease. Biochim Biophys Acta. 2016; 1862, 5: 887-900. https://doi.org/10.1016/j.bbadis.2015.12.016
39. Henry-Feugeas MC. Alzheimer’s disease in late-life dementia: a minor toxic consequence of devastating cerebrovascular dysfunction. Med Hypotheses 2008; 70, 4:866–875. https://doi.org/10.1016/j.mehy.2007.07.027
40. Liu Y, Jun H, Becker A, Wallick C, Mattke S. Detection rates of mild cognitive impairment in primary care for the United States Medicare population. J Prev Alzheimers Dis 2024; 11, 1: 7-12. DOI: 10.14283/jpad.2023.131
41. Chen Y, He Y, Han J, Wei W et al. Blood-brain barrier dysfunction and Alzheimer’s disease: associations, pathogenic mechanisms, and therapeutic potential. Front Aging Neurosci. 2023; 13, 15:1258640. https://doi.org/10.3389/fnagi.2023.1258640
42. Maksimovich IV. Cerebral Angiogenesis and Neurogenesis in The Treatment of Ischemic Stroke in Elderly and Geriatric Patients. Gerontology & Geriatric Studies. 2024; 9, 2: 745-755.
DOI: 10.31031/GGS.2024.09.000706